Amikacin use in critically ill patients requiring renal replacement therapy: the AMIDIAL-ICU study

Amikacin use in critically ill patients requiring renal replacement therapy: the AMIDIAL-ICU study

Abstract Background Acute kidney injury (AKI) requiring renal replacement therapy (RRT) is common in intensive care units (ICUs), yet optimal amikacin dosing in this context remains poorly understood. Methods We conducted a prospective observational study across 18 French hospitals from April 2020 t...

Full description

Saved in:
Bibliographic Details
Main Authors: Vincent Dupont, Bruno Mourvillier, Coralie Barbe, Vincent Legros, Mathieu Jozwiak, Hamid Merdji, Claire Dupuis, Hadrien Winiszewski, Antoine Marchalot, Guillaume Lacave, Mathilde Neuville, Anne Sagnier, François Barbier, Carine Thivilier, Stéphanie Ruiz, Roland Smonig, Jeremy Rosman, Laurent Argaud, Steven Grangé, Benjamine Sarton, Patrick Chillet, Guillaume Voiriot, Lukshe Kanagaratnam, Zoubir Djerada
Format: Article
Language:English
Published: SpringerOpen 2025-03-01
Series:Annals of Intensive Care
Subjects:
Amikacin
Aminoglycoside
Renal replacement therapy
Intensive care unit
Pharmacokinetic
Online Access:https://doi.org/10.1186/s13613-025-01461-z
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Acute kidney injury (AKI) requiring renal replacement therapy (RRT) is common in intensive care units (ICUs), yet optimal amikacin dosing in this context remains poorly understood. Methods We conducted a prospective observational study across 18 French hospitals from April 2020 to January 2022. Adult ICU patients (aged > 18 years) receiving their first amikacin dose while on RRT were included. Data on demographics, RRT modalities, amikacin dosing, and therapeutic drug monitoring were collected. Using a pharmacokinetic modeling approach, we evaluated various amikacin regimens and simulated target attainment probabilities across different minimum inhibitory concentrations (MICs). Results A total of 111 patients were included, with approximately two-thirds receiving continuous RRT. The median amikacin dose was 27 (25–30) mg/kg. Amikacin peak (Cmax) and trough concentrations were monitored in 53 (47.8%) and 76 (68.5%) patients, respectively. Continuous RRT and a history of chronic kidney disease reduced dialytic clearance. For a MIC ≤ 4 mg/L, a 15 mg/kg amikacin dose achieved Cmax/MIC and AUC/MIC targets in ≥ 90% of patients on intermittent dialysis, while 20 mg/kg was required for those on continuous dialysis. For a MIC = 8 mg/L, a 30 mg/kg dose was necessary to achieve Cmax/MIC ≥ 8. Conclusions Our findings highlight suboptimal adherence to amikacin monitoring guidelines in ICU patients on RRT. Using pharmacokinetic modeling, we identified amikacin dosing recommendations ranging from 15 to 35 mg/kg to optimize efficacy and minimize risks, depending on MIC and dialysis modality.
ISSN:2110-5820

Similar Items